Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study

Area of Science:

• Pharmacogenetics
• Neuroscience
• Clinical Psychiatry

Background:

• Individual variability in antidepressant response is partly due to pharmacogenetic factors.
• P-glycoprotein (P-GP), influenced by the ABCB1 C3435T polymorphism (rs1045642), affects drug penetration at the blood-brain barrier.
• The 3435CC genotype is associated with higher P-GP expression, potentially impacting antidepressant efficacy and safety.

Purpose of the Study:

• To investigate the association between the ABCB1 C3435T polymorphism and antidepressant response in major depressive disorder.
• To determine if the 3435CC genotype influences antidepressant efficacy and tolerance compared to 3435CT and 3435TT genotypes.

Main Methods:

• A prospective, naturalistic 4-week study involving 117 inpatients with major depressive episodes.
• Antidepressant response assessed via Hamilton Depression Rating Scale, Beck Depression Inventory, Clinician Global Impression Improvement, Therapeutic Index, and weight change.
• ABCB1 genotyping performed using the Taqman method; clinical assessments were blinded to genotype results.

Main Results:

• No statistically significant effect of the ABCB1 C3435T polymorphism (position 3435) on antidepressant efficacy was observed.
• The study also found no significant impact of this polymorphism on the safety or tolerance of antidepressant treatments.

Conclusions:

• Results do not support a role for the ABCB1 C3435T polymorphism in the therapeutic response or safety of antidepressants under naturalistic conditions.
• These findings align with previous studies on antidepressant efficacy but contrast with some in vitro data on P-GP's influence on drug concentrations.
• Methodological limitations may contribute to the observed negative results, warranting further investigation.